Amgen

Total Lobbying Efforts: 20

All Officials
Select methods...

Lobbying Records (Page 1 of 2)

2025-09-17
Politician(s) lobbied: Billy Kelleher (MEP), European Parliament
Intent: Secure meeting with MEP Kelleher to discuss EU General Pharma Legislation, Critical Medicines Act, and the upcoming Biotech Act
Methods: Email
Details by Method
Method not specified
Requested a meeting with MEP Kelleher to introduce Amgen and discuss EU General Pharma Legislation
Method not specified
Critical Medicines Act
Method not specified
and the upcoming Biotech Act
2025-09-17
Politician(s) lobbied: Laura Mannion (Special Advisor), Department of Enterprise, Trade and Employment; Peter Burke (Minister), Department of Enterprise, Trade and Employment
Intent: Provide education on Critical Medicines Act and other biopharma industry topics
Methods: Meeting
Details by Method
Method not specified
Discussion of Critical Medicines Act and other biopharma industry topics
2025-05-20
Politician(s) lobbied: Micheál Martin (Taoiseach), Dáil Éireann, the Oireachtas
Intent: Share with an Taoiseach our views on trade policy and impact on the pharmaceuticals sector
Methods: Phone call
Details by Method
Method not specified
Conversation on trade policy and the impact on the pharmaceuticals sector
2025-05-20
Politician(s) lobbied: Billy Kelleher (MEP), European Parliament
Intent: Secure meeting with MEP Billy Kelleher to discuss EU legislation
Methods: Email
Details by Method
Method not specified
Email requesting a meeting with MEP Billy Kelleher to discuss EU legislation such as the Critical Medicines Act and upcoming Biotech Act
2025-05-20
Politician(s) lobbied: Cynthia Ní Mhurchú (MEP), European Parliament
Intent: Share information with MEP Cynthia NÍ MHURCHÚ on EU legislation
Methods: Meeting
Details by Method
Method not specified
Meeting with MEP Cynthia NÍ MHURCHÚ on EU legislation such as the Critical Medicines Act and upcoming Biotech Act
2025-01-17
Politician(s) lobbied: Peter Burke (Minister), Department of Enterprise, Trade and Employment; Pauline Mulligan (Assistant Secretary), Department of Enterprise, Trade and Employment
Intent: To discuss with Minister Burke Amgen's current and future investments in Ireland and emerging public policy issues of interest
Methods: Meeting
Details by Method
Method not specified
Discussed Amgen's current and future investments in Ireland; discussed EU Pharma Legislation.
2025-01-17
Politician(s) lobbied: Peter Burke (Minister), Department of Enterprise, Trade and Employment
Intent: Meet with Minister Burke to discuss EU pharmaceutical legislation, market access to innovative medicines, and Amgen's manufacturing footprint
Methods: Meeting
Details by Method
Method not specified
Discussed EU pharmaceutical legislation
Method not specified
market access to innovative medicines
Method not specified
and Amgen's manufacturing footprint in Ireland
2025-01-17
Politician(s) lobbied: Simon Harris (An Taoiseach), Department of the Taoiseach; Max Murphy (Special Adviser), Department of the Taoiseach
Intent: Meet with the Taoiseach to discuss EU pharmaceutical legislation, IP, market access to innovative medicines, and Amgen's manufacturing footprint in Ireland
Methods: Meeting
Details by Method
Method not specified
Discussed EU pharmaceutical legislation
Method not specified
IP
Method not specified
market access to innovative medicines
Method not specified
and Amgen's manufacturing footprint in Ireland
2025-01-17
Politician(s) lobbied: Billy Kelleher (MEP), European Parliament
Intent: Participate in hosted roundtable event
Methods: Event / Reception
Details by Method
Method not specified
Discussed EU competitiveness for biopharmaceutical industry investments at ALDE 2024 party conference roundtable; discussed Biotech Act
Method not specified
EU Pharma Legislation
Method not specified
and Draghi Report.
2025-01-17
Politician(s) lobbied: Seán Kelly (MEP), European Parliament
Intent: Discussion on importance of improving EU competitiveness
Methods: Meeting
Details by Method
Method not specified
Discussed regulation
Method not specified
need to keep EU competitive and support more clinical trials in Europe as part of AmCham EU delgation